3-甲磺酰氨基苯甲醛 | 55512-05-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-甲磺酰氨基苯甲醛
• 中文别名: 3-甲磺酰胺基苯甲醛
• 英文名称: N-(3-formylphenyl)methanesulfonamide
• 英文别名: m-(methylsulfonylamino)benzaldehyde
• CAS: 55512-05-5
• 化学式: C₈H₉NO₃S
• mdl: MFCD03198179
• 分子量: 199.23
• InChiKey: CBDSSTWZEANOCR-UHFFFAOYSA-N

物化性质

• 熔点：
  146 °C
• 沸点：
  348.6±44.0 °C(Predicted)
• 密度：
  1.407±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  71.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2935009090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温且干燥

SDS

Name:	n-(3-Formylphenyl)methanesulfonamide Material Safety Data Sheet
Synonym:	None Known
CAS:	55512-05-5

Section 1 - Chemical Product MSDS Name:n-(3-Formylphenyl)methanesulfonamide Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
55512-05-5	n-(3-Formylphenyl)methanesulfonamide	97+%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 42

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed. May cause sensitization by inhalation.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
The toxicological properties of this substance have not been fully investigated.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May cause respiratory sensitization.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
Get medical aid. In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
Do not induce vomiting. If victim is conscious and alert, give 2-4 cupfuls of milk or water. Never give anything by mouth to an unconscious person. Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 55512-05-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Off white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 146 - 147 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H9NO3S
Molecular Weight: 199.23

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, excess heat.
Incompatibilities with Other Materials:
Strong oxidizing agents, amides, strong bases.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 55512-05-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
n-(3-Formylphenyl)methanesulfonamide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 42 May cause sensitization by inhalation.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 55512-05-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 55512-05-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 55512-05-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-甲磺酰氨基苯甲醛 在 氯化亚砜 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 rac-N-[3-(1-chloroethyl)phenyl]methanesulfonamide
  参考文献：
  名称：

  SUBSTITUTED DICYANOPYRIDINES AND USE THEREOF

  摘要：

  本申请涉及新型取代二氰基吡啶，其制备方法，它们用于治疗和/或预防疾病的用途，以及用于制备治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防心血管疾病的用途。

  公开号：

  US20130210795A1
• 作为产物：
  描述：

  3-氨基苯甲酸甲酯 在 lithium aluminium tetrahydride 、 重铬酸吡啶 作用下， 以 四氢呋喃 、 吡啶 、 二氯甲烷 为溶剂， 反应 42.0h， 生成 3-甲磺酰氨基苯甲醛
  参考文献：
  名称：

  具有理想理化特性和强抑制肝细胞癌生长活性的6-氟苄叉亚吲哚满酮的N'-烷基氨基磺酰基类似物

  摘要：

  据报道，亚苄基吲哚酮6-氯-3-（3'-三氟甲基亚苄基）-1,3-二氢吲哚-2-一（4）对肝细胞癌（HCC）表现出有效的选择性生长抑制作用。证实性证据支持多受体酪氨酸激酶（RTK）抑制是一种可能的作用方式。然而，较差的物理化学性质4限制了它的赞助作为先导化合物。在这项研究中，对4的修饰进行了研究，以提高其效力和理化特性。发现带有3'- N-丙基氨基磺酰基取代基的6-氟亚苄基茚满酮3-12是有前途的替代品。化合物3-12 [6-氟-3-（3'-[N-丙基氨基磺酰基亚苄基] -1,3-二氢吲哚-2-1]的溶解度是4的十倍，并且对HCC细胞具有亚微摩尔的生长抑制活性。它具有凋亡作用，可抑制HuH7中多个RTK的磷酸化，其中对FGFR4和HER3的抑制作用尤为明显。在生理相关的原位HCC异种移植小鼠模型中，化合物3-12降低了肿瘤负荷。构效关系支持氟和N'-丙基氨基磺酰基部分在增强基于细胞的活性和

  DOI：

  10.1002/cmdc.201500235

文献信息

• Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
  申请人：John Varghese

  公开号：US20060014737A1

  公开（公告）日：2006-01-19

  The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

  这项发明涉及新型化合物和治疗与淀粉样变性相关的疾病、紊乱和症状的方法。淀粉样变性指与A-beta蛋白异常沉积相关的一系列疾病、紊乱和症状。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2005082890A1

  公开（公告）日：2005-09-09

  Novel inhibitors of Rho-kinases are disclosed.

  新型Rho激酶抑制剂已被披露。
• [EN] 6-AMINO-QUINOLINE-3-CARBONITRILS AS COT MODULATORS<br/>[FR] 6-AMINO-QUINOLINE-3-CARBONITRILES UTILISÉS COMME MODULATEURS DE LA KINASE COT
  申请人：GILEAD SCIENCES INC

  公开号：WO2017007694A1

  公开（公告）日：2017-01-12

  The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.

  本公开涉及一般与Cot（癌症大阪甲状腺）的调节剂以及其使用和制造方法。
• [EN] PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2012143144A1

  公开（公告）日：2012-10-26

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体的化合物的新颖化合物（I）的公式。这些化合物在治疗各种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和与激素相关的疾病。
• [EN] COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION<br/>[FR] COMPOSÉS POUR LE TRAITEMENT D'UNE INFECTION À ARÉNAVIRUS
  申请人：ARISAN THERAPEUTICS INC

  公开号：WO2016160677A1

  公开（公告）日：2016-10-06

  The present invention relates to the use of piperazinones for inhibiting arenavirus infection in humans, other mammals, or in cell culture, to methods of treating arenavirus infection such as Lassa, Bolivian, Argentine, Venezuelan, Brazilian, Chapare and Lujo hemorrhagic fevers, to methods of inhibiting the replication of arenaviruses, to methods of reducing the amount of arenaviruses, and to compositions that can be employed for such methods.

  本发明涉及使用哌嗪酮类化合物抑制人类、其他哺乳动物或细胞培养中的病毒感染，用于治疗拉沙病、玻利维亚病、阿根廷病、委内瑞拉病、巴西病、查帕雷病和卢霍出血热等病毒感染的方法，用于抑制病毒复制的方法，用于减少病毒数量的方法，以及可用于这些方法的组合物。